Last summer, my sister Becky approached me with an idea. She wanted my help building a platform at CNBC to spotlight the 30 million Americans living with a rare disease. Becky hoped that doing so would help give a voice to the millions of people that are often overlooked by the medical community … who…
Many Americans are feeling the financial pain following the expiration of enhanced federal subsidies for Affordable Care Act marketplace health insurance. About 1 in 10 people — 9% — who were enrolled in an ACA marketplace health plan last year are now uninsured following the lapse of enhanced subsidies that reduced their monthly premiums, according…
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1s are practically everywhere – roughly one in eight…
Eli Lilly shares are down 6% Tuesday and on pace for their worst day since February after an HSBC downgrade. The crux of HSBC’s call: Wall Street is too optimistic about the size of the GLP-1 obesity market. The firm’s analysts project it to be between $80 billion and $120 billion in 2032, compared with…
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters Vertex Pharmaceuticals said its experimental drug for a rare kidney condition succeeded in a Phase 3 trial, a crucial step in the company’s path to diversify beyond its main drugs for cystic fibrosis. The Boston-based drugmaker on…
A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership:…
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the…
Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from…
Thomas Fuller | SOPA Images | Lightrocket | Getty Images UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday. The official, who requested anonymity before discussing sensitive information, confirmed the agency…
We are buying 90 shares of Cardinal Health at roughly $217. Following the trade, Jim Cramer’s Charitable Trust will own 350 shares of Cardinal, increasing its weighing to about 2% from 1.46%. We may have started a new position in Cardinal Health too early this week, but the silver lining is that the stock’s drop…
